Ignite Creation Date:
2024-05-06 @ 7:42 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02583516
Status:
COMPLETED
Last Update Posted:
2020-02-17
First Post:
2015-10-08
Brief Title:
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib Continuous and Intermittent in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Sponsor:
Grupo Español Multidisciplinar de Melanoma
Organization:
Grupo Español Multidisciplinar de Melanoma
Study Overview
Official Title:
A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of two different schedules of administration of vemurafenib in combination with cobimetinib continuous and intermittent in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-005277-36 | EUDRACT_NUMBER | None | None |